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Abstract
Background: Accumulating evidence suggests that dysregulation of the immune system is involved in the pathophysiology
of autism spectrum disorders (ASD). The aim of the study was to explore immunological markers in peripheral plasma
samples from non-medicated subjects with high-functioning ASD.
Methodology/Principal Findings: A multiplex assay for cytokines and chemokines was applied to plasma samples from
male subjects with high-functioning ASD (n=28) and matched controls (n=28). Among a total of 48 analytes examined, the
plasma concentrations of IL-1b, IL-1RA, IL-5, IL-8, IL-12(p70), IL-13, IL-17 and GRO-a were significantly higher in subjects with
ASD compared with the corresponding values of matched controls after correction for multiple comparisons.
Conclusion/Significance: The results suggest that abnormal immune responses as assessed by multiplex analysis of
cytokines may serve as one of the biological trait markers for ASD.
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Introduction
Autism spectrum disorders (ASD) are a group of neurodevel-
opmental disorders characterized by pervasive abnormalities in
social interaction and communication, and repetitive and
restricted behavioral patterns and interests. ASD include autistic
disorder, Asperger’s disorder and pervasive developmental disor-
der, not otherwise specified [1]. Susceptibility to ASD is clearly
attributable to genetic factors [2], but the etiology of ASD is
unknown, and no biomarkers have yet been proven to be
characteristic of ASD.
Accumulating evidence suggests that dysregulation of the
immune system may be implicated in the pathophysiology of
ASD [3,4]. For instance, postmortem studies have shown that the
protein levels of tumor necrosis factor a (TNF-a) and interleukin
(IL)-6 [5], as well as the number of activated microglia [6], are
significantly increased in the brains of subjects with ASD
compared to controls. In addition, lipopolysaccharide-stimulated
productions of TNF-a and IL-6 have been shown to be greater in
peripheral blood mononuclear cells from subjects with ASD than
those from controls [7]. And increased levels of inflammatory
cytokines have been detected even in peripheral samples such as
serum [8–13] or plasma [14–18] of patients with ASD. These
findings suggest that the pattern of plasma cytokine levels could
serve as a useful biological marker of ASD. However, the results
of the previous studies addressing serum or plasma levels of
cytokines in ASD appear to be inconsistent, probably due to
variations in the experimental designs, diagnostic criteria used
and age ranges of the subjects, although another possible
explanation is that these inconsistencies reflect the heterogeneity
of the ASD themselves.
Recent advances in multiplex technologies have enabled
measurement of multiple analytes simultaneously. Multiplexing
provides data on a large number of analytes, even when the
sample volumes are limited [19,20]. In this study, we used a
multiplex assay to measure a series of 48 cytokines in plasma
samples from subjects with high-functioning ASD in comparison
with matched control subjects. A recent systemic serum proteome
profiling study reported that males and females with Asperger’s
disorder have distinct biomarker fingerprints [11]. Therefore, to
prevent any potential confounding effect of sex, we recruited only
males in this study. Also, cytokine profiles were only determined in
the ASD male subjects who were more than 6 years of age,
because a multiplex analysis of cytokines in plasma samples
obtained from children less than 5 years of age (the majority of
whom were males) was recently reported [14].
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Subjects
The characteristics of all participants are summarized in
Table 1. There was no significant difference in the distribution
of age (t=0.26, P=0.79) or full IQ (t=0.46, P=0.65) between the
two groups, indicating that the subject matching was successful.
Several pro-inflammatory cytokines, including TNF-a and IL-6,
are known to be produced by adipose tissue, and the plasma levels
of these cytokines have been correlated with parameters of obesity
[21]. Therefore, we measured the weight and height of all the
participants, and the body mass index (BMI) was calculated. There
were no significant inter-group differences in the weight, height, or
BMI. In subjects with ASD, 21 subjects with ASD were diagnosed
with autistic disorder and the remaining 7 were considered to have
PDD-NOS, according to the Autism Diagnostic Interview-Revised
(ADI-R) [22].
Plasma levels of cytokines and chemokines by multiplex
assay kits
The comparison of cytokine and chemokine detection is
summarized in Table 2. Among a total of 48 analytes, plasma
concentrations of IL-2, IL-15, basic FGF, GM-CSF and LIF did
not reach the detection range in either group, and these five
analytes were excluded from further analyses. Plasma levels of IL-
1b, IL-1RA, IL-5, IL-8, IL-12(p70), IL-13, IL-17 and GRO-a
were significantly higher in subjects with ASD compared with the
corresponding values of matched controls after correction for
multiple comparisons. Plasma levels of IL-4, IL-7, G-CSF, IFN-c,
MIP-1b, PDGF-BB, TNF-a, HGF and VEGF tended to be
greater in the ASD group than in the control groups, but after
correction for multiple comparisons, the differences did not reach
the level of statistical significance. The mean levels of fold changes
of the cytokines that differed significantly between the two groups
are summarized in Figure 1.
We then examined the correlations between plasma levels of IL-
1b, IL-1RA, IL-5, IL-12(p70), IL-13, IL-17 and GRO-a and
clinical variables in the subjects with ASD. There were no
statistically significant correlations between the plasma levels of
analytes and clinical variables, including age, weight, height, BMI,
IQ (full, verbal and performance) and severities in autistic
symptoms as assessed by the ADI-R. When correlation coefficients
were evaluated among the 7 analytes that showed significant
elevation in ASD, there were significant correlations between IL-
1b and IL-1RA (Pearson’s r=.626, P,0.001), between IL-5 and
IL-13 (r=.497, P=0.007), between IL-13 and IL-12(p70) (r=.747,
P,0.001) and between IL-8 and GRO-a (r=.415, P=0.028).
Discussion
In the present study, plasma levels of IL-1b, IL-1RA, IL-5, IL-8,
IL-12(p70), IL-13, IL-17 and GRO-a in the high-functioning male
subjects with ASD were significantly higher than those of carefully
matched control subjects. Our participants with ASD showed no
signs or symptoms implying inflammatory diseases and were
similar in parameters of obesity, including BMI, to controls. Thus,
it is likely that the elevations in plasma levels of those analytes were
significantly associated with the diagnosis of ASD. These results
are in line with the studies mentioned above, which reported
altered immune responses in individuals with ASD [3,4]. The fold
changes of each analyte, however, ranged from 1.5 to 2.5, which
values were far lower than those of inflammatory or autoimmune
diseases. In addition, none of the analyte plasma levels were
correlated with the severity of autistic symptoms. Therefore, it was
suggested that the elevation of cytokines observed here may
represent an abnormal steady-state immune response in subjects
with ASD, and that such a multiplex analysis of cytokines may
serve as one of the biological trait markers for the disorder.
Plasma levels of IL-1b and IL-1RA were elevated in ASD
IL-1b is a pro-inflammatory cytokine produced by various
sources, including monocytes, macrophages, dendritic cells,
neutrophil leukocytes and endothelial cells [23]. Among previous
reports, two studies that examined serum levels of selected
cytokines, i.e., IL-1 [12] and IL-1b [24], in autistic subjects
reported no change. However, two other recent studies using
multiplex assay in ASD have demonstrated a significant increase
in plasma IL-1b levels in 2- to 5-year-old children with ASD [14]
or in serum IL-1b levels in adults with Asperger’s syndrome [11].
Given the wide variety of functions of IL-1b as an important
mediator of inflammatory response, including cell proliferation,
differentiation and apoptosis [23], it is not surprising that this
cytokine can serve as a marker for abnormal response in subjects
with ASD. On the other hand, IL-1RA binds to the cell surface IL-
1 receptor, inhibits the activities of IL-1b, and modulates IL-1-
Table 1. Demographic and clinical characteristics.
Characteristic Mean (SD) [Range]
Control, N=28 ASD, N=28
Age, years 12.3 (2.3) [7–15] 12.1 (3.3) [7–15]
Full IQ 101.5 (11.5) [82–124] 99.6 (18.6) [72–136]
Height, cm 149.6 (12.5) [121.4–172.8] 147.1 (17.0) [110.0–175.0]
Weight, kg 40.4 (10.6) [24.0–62.0] 40.4 (13.2) [17.5–72.4]
BMI, kg/m
2 17.7 (2.4) [14.4–25.3] 18.1 (2.6) [13.9–24.2]
Scores on Autism Diagnostic Interview-Revised
Domain A (social) N/A 19.9 (5.2) [9–27]
Domain BV (communication) N/A 13.7 (4.0) [8–21]
Domain C (stereotype) N/A 5.6 (2.2) [3–10]
Domain D (age of onset) N/A 3.2 (1.1) [1–5]
Abbreviations: ASD, autism spectrum disorder; IQ, intelligence quotient; BMI, body-mass index; and N/A, not applicable.
doi:10.1371/journal.pone.0020470.t001
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Control group (n=28) ASD group (n=28) FDR- corrected P value
Analytes mean SD mean SD t value
Group I
IL-1b 1.1 0.8 1.7 0.8 22.616 *0.049
IL-1RA 85.4 49.2 135.0 43.4 24.002 *0.003
IL-2 BDR BDR - -
IL-4 2.1 0.9 2.7 0.9 22.487 0.06
IL-5 2.8 1.4 3.8 1.3 22.906 *0.033
IL-6 5.9 3.2 6.8 2.4 21.207 0.37
IL-7 10.8 3.1 12.8 3.4 22.201 0.09
IL-8 8.7 3.7 11.6 2.5 23.391 *0.014
IL-9 13.0 10.1 14.8 9.9 20.672 0.68
IL-10 2.5 1.8 2.9 1.4 21.039 0.45
IL-12 (p70) 21.3 12.6 38.1 13.7 24.784 *0.001
IL-13 11.8 5.2 16.3 5.0 23.329 *0.011
IL-15 BDR BDR - -
IL-17 7.2 4.8 17.7 11.9 24.287 *0.002
Eotaxin 86.7 50.8 107.6 35.3 21.789 0.16
Basic FGF BDR BDR - -
G-CSF 4.8 3.4 6.9 3.2 22.368 0.07
GM-CSF BDR BDR - -
IFN-c 80.0 46.4 107.2 49.6 22.123 0.10
IP-10 1912.2 3202.5 1075.1 322.0 1.376 0.33
MCP-1 26.4 17.3 28.2 13.9 20.419 0.83
MIP-1a 6.5 2.6 6.7 2.8 20.227 0.91
MIP-1b 125.0 45.3 159.8 57.1 22.527 0.06
PDGF-BB 11053.2 3023.3 12465.3 1548.4 22.200 0.09
RANTES 6303.5 809.6 6103.5 598.4 1.051 0.46
TNF-a 8.6 9.1 18.0 19.6 22.316 0.08
VEGF 74.3 65.6 124.9 75.4 22.682 0.05
Group II
CTACK 555.8 138.7 606.1 145.8 21.324 0.33
GRO-a 60.5 38.3 99.0 47.4 23.347 *0.013
HGF 213.1 83.5 266.0 66.9 22.619 0.06
IFN-a2 38.4 11.1 38.1 8.2 0.150 0.92
IL-1a 0.5 0.4 0.6 0.4 20.990 0.47
IL-2Ra 59.6 20.0 56.3 22.2 0.579 0.76
IL-3 17.1 16.6 17.3 9.9 20.051 0.96
IL-12 (p40) 43.4 23.2 56.2 26.8 21.907 0.15
IL-16 210.8 90.0 220.6 73.1 20.447 0.83
IL-18 60.3 24.3 61.3 17.2 20.171 0.93
LIF BDR BDR - -
MCP-3 7.2 3.4 5.8 3.7 1.443 0.30
M-CSF 10.7 7.2 13.2 7.6 21.259 0.35
MIF 78.3 31.3 81.0 28.1 20.333 0.88
MIG 415.2 270.8 471.3 520.5 20.505 0.80
b-NGF 3.1 1.9 3.1 1.0 0.059 0.98
SCF 144.0 24.3 150.3 39.3 20.718 0.68
SCGF-b 29762.4 6331.6 32684.0 5613.8 21.827 0.16
SDF-1a 162.7 55.7 180.8 43.6 21.347 0.33
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1b in subjects with ASD were significantly and positively
correlated with those of IL-1RA, suggesting that IL-1RA might
have increased as a negative feedback regulator in response to the
elevation of IL-1b levels in ASD.
Increases in plasma levels of IL-5, IL-13 and IL-12p70 in
ASD
IL-5 is mainly produced by T helper 2 (Th2) cells and mast
cells, and belongs to the Th2 cytokine family [25]. IL-5
stimulates B cells to secrete immunoglobulins and is also a
mediator of eosinophil differentiation and activation. Previous
studies have reported eosinophilia in children with autism
[26,27], though a negative result has also been reported [28].
IL-13 is another Th2 cytokine that stimulates B cells to secrete
IgE, which is an important mediator of allergic inflammation. A
trend toward elevation in plasma levels of IL-4, the major Th2
cytokine, was also observed in the current study (t=22.49,
corrected P=0.06, see Table 2). In contrast, plasma levels of
IFN-c and IL-2, which are Th1 cytokines, were similar between
subjects with ASD and controls. Plasma levels of IL-2 and IFN-c
have been reported to be increased in autism (n=20, mean
age=10.7 years) [17]. However, since none of the other studies
found elevations of IL-2 or IFN-c in peripheral samples
[9,11,14,18], it was suggested that elevation of these Th1
cytokines may not be common in subjects with ASD. Our
findings of increased levels of Th2 cytokines without corre-
sponding changes in Th1 cytokines were consistent with previous
in vitro studies which demonstrated Th2-preferred responses after
stimulation in peripheral blood monocytes from subjects with
ASD [26,29]. Since Th2 cells have been shown to play a role in
the pathogenesis of allergy [30], our current findings are not
inconsistent with the fact that allergy is a common clinical
problem in individuals with ASD [31,32].
Figure 1. Fold changes of analytes measured by multiplex assay kits in subjects with autism spectrum disorder. The results represent
the % concentration relative to the mean concentration of each analyte in the control group (dashed line in red). Data are expressed as the mean plus
standard error of the mean.
doi:10.1371/journal.pone.0020470.g001
Control group (n=28) ASD group (n=28) FDR- corrected P value
Analytes mean SD mean SD t value
TNF-b 3.4 4.6 3.1 3.4 0.285 0.88
TRAIL 160.7 58.9 133.9 48.9 1.851 0.16
Concentrations of analytes are shown in [pg/ml]. Note the statistically significant difference between the two groups (*P,0.05 after FDR correction for multiple
comparisons). Abbreviations: ASD, autism spectrum disorder; BDR, below the detection range; FDR, false discovery rate; and SD, standard deviation.
doi:10.1371/journal.pone.0020470.t002
Table 2. Cont.
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subunits, p35 and p40 [33]. Our current finding of elevated
plasma levels of IL-12(p70) is consistent with previous results in
children with autism [17] and adults with Asperger’s syndrome
[11]. IL-12(p40) has also been shown to be increased in the plasma
of children with ASD [14]. IL-12(p70) is an immunoregulatory
cytokine that is produced mainly by B cells and by monocytes, and
is involved in the differentiation of naive T cells into Th1 cells
[33]. The elevated levels of plasma IL-12 in ASD might be an
unsuccessful compensation for the above-mentioned Th1/Th2
imbalance in subjects with ASD.
Increased plasma levels of IL-17, IL-8 and GRO-a in ASD
Outside the Th1/Th2 cell paradigm, a distinct T helper cell subset
that produces IL-17 has recentlybeendiscovered, and isknown asthe
Th17 cell subset [34]. Th17 cells are responsive to IL23 and secrete
IL-17. Enstrom and his colleagues [15] have reported that plasma IL-
17 levelsin2- to 5-year-old children with autismwere similar to those
in controls, but the IL-23 levels were decreased in the children with
autism. Researchers from the same group also examined peripheral
blood monocytes from subjects with ASD and found that PHA-
stimulated release of IL-23, but not IL-17, was lower in subjects with
ASD than in controls [35]. The discrepancy between our study and
the previous report by Enstrom et al. [15] presumably reflects the
differences in the age of participants and experimental designs. In
addition, because the kits we used for multiplex assay did not include
IL-23 as an analyte, further studies will be needed to examine the
effects of this factor. Interestingly enough, however, recent findings
suggest that IL-1b, the plasma levels of which were increased in our
subjects with ASD, plays an important role in Th17 cell
differentiation and IL-17 secretion [36,37].
Both IL-8 and GRO-a are chemokines produced by macro-
phages and other cell types, such as epithelial and endothelial cells.
These chemokines have chemotactic activity on neutrophils and
play important roles in the innate immune response. Previous
studies have examined IL-8 levels in plasma or serum, and found
either increases [14] or no change [11,38] in peripheral IL-8
levels. With regard to GRO-a, there has been no report showing a
significant difference as compared to controls. The reason why
these chemokines are increased in subjects with ASD is currently
unknown. However, IL-17 is known to be a potent mediator of
production of IL-8 and GRO-a from epithelial cells [34]. Since
IL-8 and GRO-a function as chemotaxins of these chemokines, its
elevation in the peripheral circulation suggests an activation of
innate immunity. That is, the elevation in plasma IL-8 and GRO-
a might have resulted from IL-17 secretion by Th17 cells activated
in response to subclinical infections in epithelial or endothelial cells
in our subjects with ASD.
Limitations
There were limitations in the present study. The small sample
size renders the data presented here preliminary, and a larger
study with more subjects with ASD will be necessary. However,
recruitment for the current study was limited to a group of high-
functioning subjects with ASD, none of whom were given
psychotropic drugs. Therefore, our data are free from possible
confounding factors and thus reflect a certain common immuno-
logical pathology among people with ASD.
Materials and Methods
Subjects
Twenty-eight male subjects with ASD and 28 healthy male
controls participated in this study. All the participants were
Japanese, born and living in restricted areas of central Japan,
including Aichi, Gifu, and Shizuoka prefectures. Based on
interviews and available information, including hospital records,
diagnoses of ASD were made by an experienced child psychiatrist
(TS) based on the DSM-IV-TR criteria [1]. The ADI-R [22] was
also conducted by two of the authors (KJT and KM), both of
whom have an established reliability of diagnosing autism with the
Japanese version of ADI-R. ADI-R is a semi-structured interview
conducted with a parent, usually the mother, and is used to
confirm the diagnosis and also to evaluate the core symptoms of
ASD. The ADI-R domain A score quantifies impairment in social
interaction, the domain BV score quantifies impairment in
communication, and the domain C score quantifies restricted,
repetitive and stereotyped patterns of behavior and interests. The
ADI-R domain D corresponds to the age of onset criterion for
autistic disorder. We also used the third edition of the Wechsler
Intelligence Scale for Children [39] to evaluate the intelligence
quotient (IQ) of all the participants. Co-morbid psychiatric
illnesses were excluded by means of the Structured Clinical
Interview for DSM-IV (SCID) [40]. Participants were excluded
from the study if they had any symptoms of inflammation, a
diagnosis of fragile X syndrome, epileptic seizures, obsessive-
compulsive disorder, affective disorders, IQ of lower than 70, or
any additional psychiatric or neurological diagnoses. None of the
participants had ever received psychoactive medications before
this study. Healthy control subjects were recruited locally by
advertisement. All control subjects underwent a comprehensive
assessment of their medical history to eliminate individuals with
any neurological or other medical disorders. SCID was also
conducted to scrutinize any personal or family history of past or
present mental illness. None of the comparison subjects initially
recruited was found to fulfill any of these exclusion criteria. This
study was approved by the ethics committee of the Hamamatsu
University School of Medicine. All participants as well as their
guardians were given a complete description of the study, and
provided written informed consent before enrollment.
Blood sampling and multiplex assay
Fasting blood samples from all the participants were obtained
between 11:00 and noon by venipuncture and collected into
EDTA-containing tubes. Immediately after the sampling, samples
were centrifuged for 10 min at 4uC, divided into 200-mlo f
aliquots, and stored at 280uC until use. The mean time interval
for preparation of plasma from blood samples was 4.5 min (3 to
6 min). Multiplex kits for measuring cytokines and chemokines
were purchased from Bio-Rad (Bio-Plex Pro Human Cytokine
Group I [27-plex] and Group II [21-plex] panels; Bio-Rad,
Hercules, CA). The kits were used per the manufacturer’s
instructions. Plasma samples were diluted using the appropriate
sample diluents provided in each kit in accordance with the
manufacturer’s instructions. Concentrations (pg/ml) of different
analytes in the plasma samples were determined by using the
standard curves generated in the multiplex assays. Each standard
curve was generated using eight points of concentrations, and a
nonlinear least squares minimization algorithm was used for the
curve fitting by the five-parameter logistic equation and to
determine the high and low limits of detection. Data points for
analytes that were occasionally above or below the detection range
were discarded.
Data analysis
Comparisons of concentrations of analytes between subjects
with ASD and controls were made by an unpaired t-test after
confirming that there were no statistically significant differences in
Plasma Cytokines in Autism Spectrum Disorders
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considered to be statistically significant after adjustment for the
false discovery rate (FDR) for multiple comparisons using the
Benjamin-Hochberg procedure. Evaluation of relationships be-
tween plasma levels of analytes and clinical variables among
subjects with autism spectrum disorder was performed with
Pearson’s r correlation coefficient. In the correlation analysis,
values of P,0.05 were regarded as statistically significant. All
statistical analyses were performed using SPSS statistics software
(version 17; SPSS K.K., Tokyo, Japan).
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